Source https://www.fightaging.org/archives/2022/04/arguing-for-more-and-more-rigorous-drug-repurposing-efforts-to-slow-aging/
The authors of today’s open access paper argue for much greater effort to be directed towards the repurposing of existing drugs with the goal of slowing aging. I have mixed feelings about the prevalence of drug repurposing in the pharmaceutical industry. The FDA makes it so very expensive to introduce any new drug that industry of course responds to the incentives and spends a great deal of time digging through the existing library of approved drugs in search of those that can be used in different circumstances. It is a great deal easier to take a drug with established safety data and seek approval for a new use than it is to carry out the same regulatory process for a new drug.
On the one hand, this search of existing drug databases can turn up items like the <a href="https://www.fightaging.org/archives/2015…
Source https://www.fightaging.org/archives/2022/04/arguing-for-more-and-more-rigorous-drug-repurposing-efforts-to-slow-aging/
The authors of today’s open access paper argue for much greater effort to be directed towards the repurposing of existing drugs with the goal of slowing aging. I have mixed feelings about the prevalence of drug repurposing in the pharmaceutical industry. The FDA makes it so very expensive to introduce any new drug that industry of course responds to the incentives and spends a great deal of time digging through the existing library of approved drugs in search of those that can be used in different circumstances. It is a great deal easier to take a drug with established safety data and seek approval for a new use than it is to carry out the same regulatory process for a new drug.
On the one hand, this search of existing drug databases can turn up items like the <a href="https://www.fightaging.org/archives/2015…
What Do You Think?
comments